Q1. CHOLESTATIC JAUNDICE

Definition

Pathophysiology

• Unconjugated bilirubin: insoluble, albumin-bound, cannot be excreted in urine. Accumulates in hemolysis, immaturity of conjugating enzymes.
• Conjugated bilirubin: water-soluble, loosely albumin-bound, excreted in urine. Accumulates in cholestasis and hepatocellular disease.

• Hepatocellular disease
• Bile duct injury
• Biliary obstruction

Clinical Features

• Yellow discoloration of skin and sclera (icterus)
• Pruritus (from bile salt deposition in skin)
• Skin xanthomas (focal cholesterol accumulation)
• Intestinal malabsorption: deficiencies of fat-soluble vitamins A, D, E, and K
• Dark urine (conjugated bilirubin is water-soluble and excreted in urine)
• Pale/acholic stools (absence of bile pigment in gut)

Laboratory Findings

• Elevated serum alkaline phosphatase (ALP) - present on apical membranes of hepatocytes and cholangiocytes
• Elevated gamma-glutamyl transpeptidase (GGT)
• Elevated conjugated (direct) bilirubin
• Prothrombin time may be prolonged (vitamin K malabsorption)

Causes

Extrahepatic (Obstructive) Causes

• Adults: cholelithiasis (gallstones - most common), tumors (carcinoma of head of pancreas, cholangiocarcinoma), postsurgical strictures
• Children: biliary atresia, cystic fibrosis, choledochal cysts, paucity of bile duct syndromes

Intrahepatic Causes

• Primary biliary cirrhosis (PBC)
• Primary sclerosing cholangitis (PSC)
• Drug-induced cholestasis
• Intrahepatic cholestasis of pregnancy
• Neonatal hepatitis

Morphology (Robbins)

1. Bile pigment accumulation in hepatic parenchyma - elongated green-brown plugs of bile in dilated bile canaliculi
2. Feathery degeneration of hepatocytes - droplets of bile pigment accumulate within hepatocytes giving a fine, foamy appearance
3. Kupffer cell hypertrophy - bile extravasated from ruptured canaliculi is phagocytosed by Kupffer cells
4. Apoptotic hepatocytes - occasional

• Distension and dilation of upstream bile ducts
• Ductular reactions at portal-parenchymal interface
• Stromal edema and neutrophils at portal tracts

• Influx of periductular neutrophils into bile duct epithelium and lumen - this is the hallmark

• Periportal fibrosis
• Feathery degeneration of periportal hepatocytes with Mallory hyaline bodies
• Bile infarcts (due to detergent effects of extravasated bile)
• Eventually: secondary biliary cirrhosis (obstructive biliary cirrhosis)

Neonatal Cholestasis

1. Cholangiopathies - primarily biliary atresia (requires surgical intervention)
2. Neonatal hepatitis - metabolic, toxic, genetic, infectious causes (surgery contraindicated)

Q2. SEROLOGICAL MARKERS OF HEPATITIS B AND DIAGNOSTIC SIGNIFICANCE

HBV Genome and Antigens Produced

Serological Markers and Their Diagnostic Significance

1. HBsAg (Hepatitis B Surface Antigen)

• First marker to appear in serum - appears before onset of symptoms
• Peaks during symptomatic disease
• Normally becomes undetectable within 12 weeks (may persist up to 24 weeks)
• Persistence beyond 6 months = chronic HBV infection / carrier state
• Used in vaccine preparation
• Significance: Screening test for HBV; its persistence indicates chronicity

2. Anti-HBs (Antibody to HBsAg)

• Appears after acute disease resolves, a few weeks to months after HBsAg disappears - this gap is the "window period" where neither HBsAg nor anti-HBs is detectable
• Persists for life - confers immunity
• Appears after vaccination
• NOT produced in cases progressing to chronic liver disease
• Significance: Indicates recovery, immunity (natural or vaccine-induced); its absence in chronically infected patients confirms failure to clear infection

3. HBcAg (Hepatitis B Core Antigen)

• Not detectable in serum - remains within hepatocytes, participates in virion assembly
• Detected only in liver biopsy tissue
• Significance: Intrahepatic marker; anti-HBc antibodies (not HBcAg itself) are the key serum markers

4. Anti-HBc (Antibody to HBcAg)

IgM Anti-HBc

• Becomes detectable shortly before onset of symptoms, concurrent with elevated serum aminotransferases
• The key marker in the window period (when HBsAg has disappeared but anti-HBs has not yet appeared)
• Over months, IgM anti-HBc is replaced by IgG anti-HBc
• Significance: Indicates acute/recent HBV infection; only marker present during window period

IgG Anti-HBc

• Replaces IgM anti-HBc over several months
• Persists indefinitely in both recovered and chronically infected individuals
• Part of "total anti-HBc"
• Significance: Indicates past exposure to HBV (cannot distinguish acute from chronic by itself)

5. HBeAg (Hepatitis B e Antigen)

• Appears in serum soon after HBsAg - signifies active viral replication and high infectivity
• Persistence of HBeAg = indicator of progression to chronic hepatitis
• Significance: Marker of high viral replication and infectivity; its persistence predicts chronicity

6. Anti-HBe (Antibody to HBeAg)

• Appearance of anti-HBe implies acute infection has peaked and is waning
• Seroconversion from HBeAg to anti-HBe = favorable sign (reduced replication)
• Significance: Indicates declining viral replication; favorable prognostic sign in acute infection

7. HBV DNA

• Appears soon after HBsAg - most sensitive marker of active viral replication
• Detected by PCR
• Persists in chronic infection
• Used to monitor antiviral therapy response
• Significance: Gold standard for assessing viral load and treatment response

Serological Patterns Summary Table

Clinical Outcomes of HBV Infection (Robbins)

1. Acute hepatitis with recovery and viral clearance
2. Nonprogressive chronic hepatitis
3. Progressive chronic disease ending in cirrhosis
4. Fulminant hepatitis with massive liver necrosis (~0.1-0.5%)
5. Asymptomatic "healthy" carrier state

• Neonates infected perinatally: ~90% risk of chronicity
• Adults acutely infected: only 5-10% risk of chronicity

CHOLESTATIC JAUNDICE - Comprehensive Answer

Definition

Clinical Features

• Yellow discoloration of skin and sclera (icterus)
• Pruritus (bile salt deposition in skin)
• Skin xanthomas (cholesterol accumulation)
• Dark urine (conjugated bilirubin is water-soluble, excreted in urine)
• Pale/acholic stools (no bile reaching gut)
• Malabsorption of fat-soluble vitamins A, D, E, K

Laboratory Findings

• Elevated serum alkaline phosphatase (ALP) and GGT - key cholestatic markers
• Elevated conjugated (direct) bilirubin
• Prolonged prothrombin time (vitamin K malabsorption)

General Morphology of Cholestasis

1. Bile plugs - elongated green-brown plugs in dilated bile canaliculi
2. Feathery degeneration - foamy cytoplasmic swelling of hepatocytes with bile droplet accumulation
3. Kupffer cell hypertrophy - phagocytose extravasated bile from ruptured canaliculi
4. Occasional apoptotic hepatocytes

A. DEFECTS IN HEPATOCELLULAR BILIRUBIN METABOLISM

1. Physiological Jaundice of the Newborn (Neonatal Jaundice)

• Treatment: Phototherapy with blue light, which converts bilirubin to a water-soluble isomer that is readily excreted in urine - this is sufficient until hepatic conjugation machinery matures
• Physiologic jaundice resolves by 2 weeks of age
• Infants with jaundice beyond 14-21 days must be evaluated for neonatal cholestasis

2. Hereditary Hyperbilirubinemia

B. LARGE BILE DUCT OBSTRUCTION

Causes

• Choledocholithiasis (gallstones) - most common
• Malignant neoplasms of biliary tree or head of pancreas (usually adenocarcinoma)
• Strictures from previous surgery or ischemic injury
• Primary sclerosing cholangitis (inflammatory injury to large intrahepatic/extrahepatic ducts)

• Biliary atresia, cystic fibrosis, choledochal cysts

Complication - Ascending Cholangitis

Morphology

• Proximal duct dilation
• Portal expansion due to edema
• Prominent ductular reaction at portal-parenchymal interface
• Infiltrating neutrophils associated with ductules - "pericholangitis"
• In ascending cholangitis: neutrophils involve the bile duct epithelium and lumens

• Fibrosis progressing to secondary (obstructive) biliary cirrhosis
• Feathery degeneration of periportal hepatocytes
• Bile pigment and Mallory hyaline in periportal hepatocytes
• Bile infarcts - from detergent effects of extravasated bile
• Superimposed ascending cholangitis in advanced disease can precipitate acute-on-chronic liver failure

C. CHOLESTASIS OF SEPSIS

1. Direct intrahepatic bacterial infection (abscess/bacterial cholangitis)
2. Ischemia due to hypotension (especially in cirrhotic liver)
3. Response to circulating microbial products - this is the mechanism most likely causing cholestasis of sepsis; particularly with gram-negative organisms

Morphology

• Canalicular cholestasis with bile plugs in dilated canaliculi
• Ductular/cholangiolar cholestasis - bile plugs within dilated canals of Hering and bile ductules at the portal-parenchymal interface
• Inflammation and hepatocellular injury are typically mild (unlike viral hepatitis)

D. PRIMARY HEPATOLITHIASIS

• Geography: Highly prevalent in East Asia (Taiwan, Japan); rare elsewhere
• Etiology: Uncertain - congenital duct abnormalities, diet, chronic infection with bacteria or parasites have all been suggested
• Complication: Chronic inflammatory injury is a risk factor for cholangiocarcinoma (particularly in Taiwan and Japan)

Morphology

• Pigmented calcium bilirubinate stones in distended intrahepatic bile ducts
• Bile ducts show chronic inflammation, mural fibrosis, and peribiliary gland hyperplasia
• Obstruction of extrahepatic ducts is NOT present
• Repeated inflammation leads to parenchymal collapse and fibrosis - can produce a mass-like lesion mimicking a tumor on imaging

E. NEONATAL CHOLESTASIS

1. Obstructive biliary disease: primarily biliary atresia
2. Non-obstructive causes: paucity of bile ducts, infectious/metabolic diseases, bile transporter defects, idiopathic neonatal hepatitis

• Ultrasound: small/absent gallbladder, fibrosis at porta hepatis
• HIDA scan with 99mTc: in biliary atresia, total lack of secretion into bile - biliary tree NOT visualized
• Liver biopsy when needed

• Inflammation and fibrosis of hepatic/common bile ducts (hallmark)
• Portal edema, ductular reaction, neutrophil infiltrates on liver biopsy
• If uncorrected: cirrhosis by 3-6 months of age

F. NON-OBSTRUCTIVE NEONATAL CHOLESTASIS

(i) Alagille Syndrome (Arteriohepatic Dysplasia)

• Autosomal dominant disorder
• Caused by loss-of-function mutations in Notch pathway genes - either JAG1 (ligand) or NOTCH2 (receptor) - both required for normal biliary tree development
• Features: Cholestasis + paucity of bile ducts + dysmorphic facies + butterfly-shaped vertebra + eye defects + cardiac defects

(ii) Inborn Errors of Metabolism

• Galactosemia
• Niemann-Pick disease

(iii) Progressive Familial Intrahepatic Cholestasis (PFIC)

• alpha-1-antitrypsin deficiency is another important nonsyndromic cause

(iv) Neonatal Hepatitis

• A broad group of conditions causing hepatitis and cholestasis
• Main entities: TORCH infections, hypopituitarism, alpha-1-antitrypsin deficiency, BSEP deficiency
• Etiology identifiable in 85-90% of cases with modern workup
• Remaining 10-15%: idiopathic neonatal hepatitis

Morphology of Non-obstructive Neonatal Cholestasis

• Hepatocanalicular cholestasis
• Giant-cell (syncytial) change - multinucleated hepatocytes (most striking feature)
• Reactive Kupffer cells
• Extramedullary hematopoiesis
• Alagille syndrome: decreased number of bile ducts in portal tracts (paucity of bile ducts)
• Cases with hepatitis: lobular inflammation and hepatocellular apoptosis/necrosis

G. AUTOIMMUNE CHOLANGIOPATHIES

1. Primary Biliary Cholangitis (PBC)

• Predominantly middle-aged women (F:M = 9:1)
• Peak incidence: 40-50 years of age
• Most common in Northern Europe (England, Scotland) and Northern United States
• Family members have increased risk

• T lymphocyte-mediated destruction of small interlobular bile ducts
• Retention of bile salts from bile duct injury causes secondary hepatocellular damage
• Antimitochondrial antibody (AMA) directed against E2 component of pyruvate dehydrogenase complex (PDC-E2) - most characteristic finding; present in 90-95% of patients
• PDC-E2-specific T cells are also present
• AMA titers do NOT correlate with disease severity or predict therapy response
• 5% of typical PBC cases are AMA-negative
• Autoantibodies against nuclear pore proteins and centromeric proteins may also be present
• Environmental triggers (infections, toxic chemicals) in genetically susceptible individuals may lead to expression of autoantigens on bile duct epithelial cells

• Florid duct lesion (hallmark) - lymphocytic infiltration + poorly formed epithelioid granulomas centered on and destroying small interlobular bile ducts
• Portal lymphoplasmacytic inflammation
• Ductular reaction
• Patchy distribution - a minority of portal tracts involved early; some portal tracts have active lesions while adjacent ducts are unaffected
• Disease progression: widespread duct loss -> portal-portal septal fibrosis -> cirrhosis
• In the absence of treatment: either progressive cholestasis/cirrhosis OR portal hypertension

• Diagnosed early due to elevated serum ALP or pruritus
• Insidious onset: fatigue and pruritus
• Hypercholesterolemia common
• Confirmed by liver biopsy (florid duct lesion is diagnostic)
• Secondary features over time: skin hyperpigmentation, xanthelasmas, steatorrhea, vitamin D malabsorption causing osteomalacia/osteoporosis
• Extrahepatic autoimmune associations: Sjogren syndrome (sicca complex; 70%), systemic sclerosis, thyroiditis, rheumatoid arthritis, Raynaud phenomenon, celiac disease
• Treatment: Oral ursodeoxycholic acid - dramatically improves outcomes and slows progression (alters bile acid pool composition)
• Liver transplantation for end-stage disease

2. Primary Sclerosing Cholangitis (PSC)

• Male predominance: 2:1 (M:F)
• Third to fifth decades of life (younger than PBC; median age ~30 years)
• Inflammatory bowel disease coexists in ~70% of PSC patients (most commonly ulcerative colitis)
• Conversely, PSC prevalence in UC patients is ~4%

• Immunologically mediated bile duct injury - T cells in periductal stroma
• HLA-B8 and other MHC allele association
• Autoantibodies: antismooth muscle antibodies and antinuclear antibodies (~75%); ANCA (pANCA) in up to 80% of affected adults
• Proposed mechanism: T cells activated in damaged UC mucosa migrate to liver, cross-react with bile duct antigen, initiate autoimmune assault on bile ducts
• In some cases associated with autoimmune pancreatitis - may represent IgG4-related disease
• First-degree relatives have increased risk

• Large ducts: neutrophilic infiltration into epithelium + chronic inflammatory background; strictures from scarring
• Small ducts: characteristic "onion-skin" circumferential periductal fibrosis around atrophic duct lumen - eventually obliterated, leaving a "tombstone scar" (fibrous remnant)
• End stage: biliary cirrhosis

• Persistent elevation of serum ALP (especially detected during routine screening in UC patients)
• Progressive fatigue, pruritus, jaundice
• Acute bouts of ascending cholangitis
• Chronic pancreatitis and chronic cholecystitis (involvement of pancreatic ducts and gallbladder)
• Gold standard for diagnosis: characteristic "beading" on MRI/MRCP of biliary tree
• No satisfactory medical treatment (unlike PBC where ursodiol helps)
• Without liver transplantation: median survival 10-12 years
• Risk of progression to cholangiocarcinoma

Comparison Table: PBC vs PSC (Robbins)

CHOLESTATIC JAUNDICE — Condensed with Flowcharts

What is Cholestasis?

Obstruction of bile channels  OR  Defect in hepatocyte bile secretion
                    ↓
        Bile accumulates in blood & tissues
                    ↓
    Conjugated hyperbilirubinemia > 2-2.5 mg/dL
                    ↓
        CHOLESTATIC JAUNDICE

Classification Overview

                    CHOLESTATIC JAUNDICE
                           │
          ┌────────────────┼────────────────┐
    Hereditary         Acquired           Neonatal
  Hyperbilirubinemia   Cholestasis        Cholestasis

1. PHYSIOLOGICAL JAUNDICE OF NEWBORN

Immature hepatic UGT1A1 enzyme at birth
            ↓
  Unconjugated hyperbilirubinemia
            ↓
  Appears Day 2-3, resolves by Day 14
            ↓
  Worsened by breast milk (deconjugating enzymes)
            ↓
  Treatment: Blue-light phototherapy
  (converts bilirubin → water-soluble isomer → excreted in urine)

⚠ Persists beyond 14-21 days → Evaluate for NEONATAL CHOLESTASIS

2. HEREDITARY HYPERBILIRUBINEMIA

                  GENETIC DEFECT IN BILIRUBIN METABOLISM
                              │
              ┌───────────────┴────────────────┐
     UNCONJUGATED                         CONJUGATED
  hyperbilirubinemia                   hyperbilirubinemia
              │                               │
    ┌─────────┴──────────┐           ┌────────┴────────┐
    │                    │           │                  │
Crigler-Najjar        Gilbert     Dubin-Johnson       Rotor
  Type 1 & 2         Syndrome      Syndrome          Syndrome
    │                    │           │                  │
Severe/absent         Reduced    MRP2 gene           Similar
 UGT1A1            UGT1A1 →     mutation →          transport
Type 1 = FATAL      Mild,       Brown-black          defect
at birth            benign      pigment in           Benign
Type 2 = Mild                   hepatocytes
                               (liver turns black)
                               Benign, AR

3. LARGE BILE DUCT OBSTRUCTION

        CAUSES OF LARGE DUCT OBSTRUCTION
                     │
        ┌────────────┴─────────────┐
      Adults                   Children
        │                          │
  • Cholelithiasis           • Biliary atresia
    (MOST COMMON)            • Cystic fibrosis
  • Pancreatic/               • Choledochal cysts
    biliary malignancy
  • Post-surgical strictures
  • PSC
        │
        ↓ MORPHOLOGY
  ┌─────────────────────────────────┐
  │ Acute:                          │
  │  • Proximal duct dilation       │
  │  • Portal edema                 │
  │  • Ductular reaction            │
  │  • Neutrophils ("pericholangitis")│
  └─────────────────────────────────┘
        ↓ (if untreated)
  ┌─────────────────────────────────┐
  │ Chronic:                        │
  │  • Feathery degeneration        │
  │  • Mallory hyaline              │
  │  • Bile infarcts                │
  │  • BILIARY CIRRHOSIS            │
  └─────────────────────────────────┘
        ↓ (superimposed infection)
  ASCENDING CHOLANGITIS
  • Fever + Chills + Jaundice
  • Neutrophils inside bile duct lumen
  • Culprits: E. coli, Enterococcus

4. CHOLESTASIS OF SEPSIS

        SEPSIS (esp. Gram-negative organisms)
                        │
        ┌───────────────┼──────────────────┐
   Direct infection   Ischemia       Circulating microbial
   (abscess/          (hypotension)  products → main cause
   cholangitis)                      of cholestasis
                                          │
                                          ↓
                              MORPHOLOGY:
                    • Canalicular cholestasis + bile plugs
                    • "Ductular/cholangiolar cholestasis"
                      (bile plugs in dilated canals of Hering)
                    • Inflammation = MILD
                      (unlike hepatitis)

5. PRIMARY HEPATOLITHIASIS

Intrahepatic bile duct stones (pigmented calcium bilirubinate)
                    │
            (East Asia - endemic)
                    │
                    ↓
    Repeated bouts of ascending cholangitis
                    │
                    ↓
   Chronic inflammation → mural fibrosis → peribiliary
           gland hyperplasia → parenchymal collapse
                    │
                    ↓
        Mass-like lesion (mimics tumor on imaging)
                    │
                    ↓
         ⚠ Risk: CHOLANGIOCARCINOMA

6. NEONATAL CHOLESTASIS

Conjugated hyperbilirubinemia persisting > 2-3 weeks
                        │
          ┌─────────────┴──────────────┐
   OBSTRUCTIVE                    NON-OBSTRUCTIVE
          │                            │
          ↓                            ↓
  (See flowchart 6A)           (See flowchart 6B)

6A. Obstructive — Extrahepatic Biliary Atresia

Presents: 2-6 weeks after birth
Jaundice + Dark urine + Acholic stools + Hepatomegaly
                    │
                    ↓
          INVESTIGATIONS:
  Ultrasound → Small/absent gallbladder
  HIDA scan (99mTc) → No biliary excretion
  Liver biopsy → Portal edema + ductular reaction
                    + neutrophils
                    │
                    ↓
          MORPHOLOGY:
  Inflammation + fibrosis of hepatic/common bile ducts
  ↓ (if uncorrected)
  CIRRHOSIS by 3-6 months of age
                    │
                    ↓
          TREATMENT:
  Kasai procedure (porto-enterostomy)
  Liver transplantation if Kasai fails

6B. Non-Obstructive Neonatal Cholestasis

           NON-OBSTRUCTIVE NEONATAL CHOLESTASIS
                           │
          ┌────────────────┼─────────────────┐
   Syndromic            Metabolic         Neonatal
   (Alagille)          /transport          Hepatitis
       │               disorders               │
       ↓                   │               Infections
  Notch pathway            ↓             (TORCH, sepsis,
  JAG1/NOTCH2         PFIC 1,2,3           UTI, syphilis)
  mutation            α1-AT deficiency   Hypopituitarism
  + Paucity of        Galactosemia       α1-AT deficiency
    bile ducts        Niemann-Pick
  + Butterfly
    vertebrae
  + Cardiac defects
  + Eye defects

           PFIC (Progressive Familial Intrahepatic Cholestasis)
           ┌────────────┬────────────┬─────────────┐
         Type 1        Type 2       Type 3
      (Byler disease) (BSEP def)  (MDR3 def)
      ATP8B1 mut.    ABCB11 mut.  ABCB4 mut.

MORPHOLOGY (all non-obstructive):
  • Hepatocanalicular cholestasis
  • GIANT CELL / SYNCYTIAL CHANGE ← most striking feature
    (multinucleated hepatocytes)
  • Reactive Kupffer cells
  • Extramedullary hematopoiesis
  • Lobular inflammation + apoptosis (hepatitis cases)
  • Alagille → PAUCITY OF BILE DUCTS in portal tracts

7. AUTOIMMUNE CHOLANGIOPATHIES

               AUTOIMMUNE CHOLANGIOPATHIES
                          │
           ┌──────────────┴──────────────┐
          PBC                           PSC
  (Primary Biliary               (Primary Sclerosing
   Cholangitis)                   Cholangitis)

Primary Biliary Cholangitis (PBC)

TARGET: Small & medium intrahepatic ducts only
              │
              ↓
  T cell-mediated destruction
  + AMA against PDC-E2 (90-95% of patients)
              │
              ↓
  WHO: Middle-aged women (F:M = 9:1), age 40-50
  WHERE: Northern Europe, Northern USA
              │
              ↓
  MORPHOLOGY:
  "FLORID DUCT LESION" ← HALLMARK
  (Lymphocytes + granulomas surrounding/destroying
   small interlobular bile ducts)
  + Portal lymphoplasmacytic infiltrate
  + Ductular reaction
  + Patchy distribution
              │
              ↓
  CLINICAL: Fatigue + Pruritus + ↑ALP
  + Hypercholesterolemia
  + Extrahepatic: Sjogren (70%), scleroderma,
    thyroiditis, RA, celiac disease
              │
              ↓
  TREATMENT: Ursodeoxycholic acid (effective)
  End-stage → Liver transplantation

Primary Sclerosing Cholangitis (PSC)

TARGET: Both intrahepatic AND extrahepatic ducts
              │
              ↓
  Immune-mediated injury (HLA-B8 association)
  pANCA positive in 80%
  T cells from UC mucosa cross-react with bile duct antigens
              │
              ↓
  WHO: Young males (M:F = 2:1), age 30-50 years
  ASSOCIATION: Ulcerative colitis in 70%
              │
              ↓
  MORPHOLOGY:
  Large ducts → Neutrophils in epithelium + strictures
  Small ducts → "ONION-SKIN" circumferential
                periductal fibrosis → duct obliteration
                → "tombstone scar"
              │
              ↓
  IMAGING (Gold standard):
  MRI/MRCP → "BEADING" pattern
  (alternating strictures + dilatations)
              │
              ↓
  CLINICAL: ↑ALP + Pruritus + Jaundice
  + Ascending cholangitis episodes
  + Chronic pancreatitis (in some)
              │
              ↓
  TREATMENT: NO effective medical treatment
  Liver transplantation → median survival 10-12 yrs
  ⚠ Risk: CHOLANGIOCARCINOMA

PBC vs PSC — Quick Comparison